2nd Digital Biomarkers and Clinical Measures in Neurology Summit

Memo

Join 100+ of your digital health and CNS clinical development peers to address the standardization and regulatory acceptance of digital tools and data analysis as endpoints in complex neurological indications, discover novel innovations for objective, sensitive, and non-invasive neurological measures, and ensure internal confidence and scalability with emerging digital technologies. Uniting Digital Health Biopharma with CNS Clinical Drug Developers to:1. Address the Standardization and Regulatory Acceptance of Digital Tools and Data Analysis as Endpoints in Complex Neurological Indications2. Discover Novel Innovations for Objective, Sensitive, and Non-Invasive Neurological Measures3. Ensure Confidence and Scalability with Emerging Digital Technologies URLs:Tickets: https://go.evvnt.com/1613893-0?pid=5569 Brochure: https://go.evvnt.com/1613893-3?pid=5569  Date and Time: On Tue, 11 Jul 2023 09:00 - Thu, 13 Jul 2023 17:00 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Drug Developers- Conference + 2 Workshops: USD 3597.00,Drug Developers- Conference + 1 Workshop: USD 3098.00,Drug Developers- Conference Only: USD 2599.00,Solution Providers- Conference + 2 Workshops: USD 5297.00,Solution Providers- Conference + 1 Workshop: USD 4548.00,Solution Providers- Conference Only: USD 3799.00 Speakers: Abhishek Pratap Head of Data Innovation, Biogen Digital Health Biogen, Allison Moore Chief Executive Officer Hereditary Neuropathy Foundation Inc, Altoida, Arvind Tewari, Former Vice President, Digital Strategy and Operations ATAI Life Sciences, Bharat Koyani, Associate Director, Patient Innovation and Digital Biomarker Lead Regeneron Pharmaceuticals Inc, Bhaskar Dutta, Head of Digital Health Program Management, Alexion Pharmaceuticals, Brian Tracey, Director, Statistics Takeda Pharmaceutical Co. Ltd., Bryan Cobb, Medical Science Director, Genentech, Charlotte Sauter, Senior Digital Health Scientist, Lundbeck, Christoph M. Kanzler, Lead Data Scientist, Upper Extremities, Digital Biomarker R and D Biogen, Eleftheria Pissadaki, Adjunct Faculty Member, New York University, Elias Abou Zeid, Principal Data Scientist, Novo Nordisk, Emrah Aras, Associate Director, Data Generation and Insights Strategy Alexion Pharmaceuticals, Inc, Gul Erdemli, Director, Global Program Regulatory, Novartis AG, Hao Zhang, Senior Manager Biomedical Engineering, Pfizer, Hui Zhang, Senior Director, Eli Lilly and Co., Ivan Clement, Associate Director, Real-World Evidence and Innovative Evidence Novartis AG, Jonas Abdel-Khalik, Senior Digital Health Scientist, Digital Health Technologies H. Lundbeck A/S, Mark Gudesblatt, Neurologist, South Shore Hospital, Matthew Czech Associate Director, Digital Science, Abbvie, Michal Melamed, Data Scientist, Advanced Analytics and AI ,Teva Pharmaceuticals, Ralph Kern, President and Chief Medical Officer, BrainStorm Cell Therapeutics, Shawn Mishra, Bioinformatics Data Scientist, Regeneron Pharmaceuticals Inc, Tairmae Kangarloo, Associate Director, Digital Strategy, Takeda Pharmaceutical Co. Ltd., Virginia Parks, Clinical Pharmacology Scientist, Servier, Vivosense, Xiangnan Dang, Director of Engineering, Digital Health R and D Eli Lilly and Co.